AA
LRMR icon

Ancora Advisors’s Larimar Therapeutics LRMR Stock Holding History

Ancora Advisors’s Portfolio LRMR Stock Details LRMR Fund Activity
Bought
Maintained
Sold
Quarter Market Value Status Shares Change in
Stake 		Trade Value Portfolio Weight Portfolio Position
2018
Q1 		– Sell
-1,667
Closed -$92K – 689
2017
Q4 		$92K Hold
1,667
– – ﹤0.01% 609
2017
Q3 		$70K Hold
1,667
– – ﹤0.01% 646
2017
Q2 		$70K Hold
1,667
– – ﹤0.01% 620
2017
Q1 		$93K Hold
1,667
– – 0.01% 605
2016
Q4 		$64K Sell
1,667
-1,083
-39% -$43.9K ﹤0.01% 736
2016
Q3 		$109K Buy
+2,750
New +$125K 0.01% 507

Other funds holding LRMR

Fidelity Investments
Fidelity Investments Boston, Massachusetts $2.3T AUM 54.33% 1-Year Est. Return
6CM
683 Capital Management New York $2.04B AUM 94.26% 1-Year Est. Return
AG
Artal Group Luxembourg $931M AUM 41.63% 1-Year Est. Return
Vanguard Group
Vanguard Group Malvern, Pennsylvania $6.9T AUM 27.45% 1-Year Est. Return
AC
Armistice Capital New York $8.17B AUM 68.82% 1-Year Est. Return
Dimensional Fund Advisors
Dimensional Fund Advisors Austin, Texas $552B AUM 44.19% 1-Year Est. Return
MP
Mangrove Partners Greenwich, Connecticut $1.52B AUM 36.54% 1-Year Est. Return
Renaissance Technologies
Renaissance Technologies New York $72.6B AUM 54.88% 1-Year Est. Return
RA
Royce & Associates New York $12.4B AUM 64.17% 1-Year Est. Return
Balyasny Asset Management
Balyasny Asset Management Chicago, Illinois $80.2B AUM 51.53% 1-Year Est. Return

Ancora Advisors's LRMR Position: Q1 2018 in Review

Ancora Advisors sold out of Larimar Therapeutics (LRMR) in Q1 2018, closing a stake of 1,667 shares — an estimated $92K sold.

Ancora Advisors first reported a position in LRMR in Q3 2016 and held it in 6 quarters. The position peaked at $109K in Q3 2016. 61 funds tracked by Wall St. Rank hold LRMR as of Q1 2018.

  • Ancora Advisors reported no remaining Larimar Therapeutics position as of Q1 2018 after selling out during the quarter.
  • Ancora Advisors sold 1,667 Larimar Therapeutics shares in Q1 2018, an estimated $92K.
  • Ancora Advisors first reported a position in Larimar Therapeutics in Q3 2016 and held it in 6 quarters.
  • Ancora Advisors's Larimar Therapeutics position peaked at $109K in Q3 2016.
  • 61 funds tracked by Wall St. Rank held Larimar Therapeutics as of Q1 2018.

Based on Ancora Advisors's 13F filing for Q1 2018, filed 15 May 2018.